Original title: With continuous top-level policies in the field of traditional Chinese medicine, what development opportunities should the industry grasp?
Under a series of intensive top-level policies, my country’s traditional Chinese medicine field may usher in major development opportunities.
The field of Chinese medicine may usher in major development opportunities under a series of intensive policies.
On December 30, the website of the State Administration of Traditional Chinese Medicine published the “Guiding Opinions of the National Medical Security Administration and the State Administration of Traditional Chinese Medicine on Medical Insurance to Support the Inheritance and Innovation and Development of Traditional Chinese Medicine” (hereinafter referred to as the “Opinions”) to further support the innovation of the Chinese medicine industry.
The largest centralized procurement in the field of proprietary Chinese medicines also came to an end on 27th. The results of the “Announcement of Centralized Procurement of Proprietary Chinese Medicines Interprovincial Alliance” involving 19 provinces showed that 111 Chinese patent medicines were selected, and the average price drop of the proposed selection was 42.27%, which was the largest The decrease was 82.63%; at the same time, the collection industry of the Chinese Patent Medicine Alliance in 6 provinces led by Guangdong has been launched.
Changes in the field of Chinese medicine are imminent. What impact will the relevant top-level policies continue to have on the Chinese medicine industry?
Chinese medicine formula granules first
The above-mentioned “Opinions” proposed that qualified Chinese medicine decoction pieces, Chinese patent medicines, and Chinese medicine preparations of medical institutions should be included in the medical insurance drug list. The equipment and use of proprietary Chinese medicines that have been negotiated by the state and included in the medical insurance catalogue will be included in the monitoring and evaluation.
So, what is the difference between Chinese patent medicine and chemical medicine, biological medicine, and high-value medical consumables?
“From the perspective of centralized procurement, the difference between proprietary Chinese medicines and the centralized procurement of high-value medical consumables in the past is that proprietary Chinese medicines have several outstanding characteristics.” Liang Jialin, secretary general of the Value Medical Advisory Committee, said in an interview with China Business News For example, in the past, centralized procurement of medicines and high-value medical consumables, in addition to high R&D investment, their production costs will be very high unless some rare raw materials and spare parts are used, and their final costs will not be too high. high. However, for proprietary Chinese medicines, since its upstream is traditional Chinese medicines, and some of them are precious Chinese medicines, this has high requirements on the source and place of production, so special attention should be paid to the collection and procurement of Chinese patent medicines to avoid price deficiencies. The quality of Chinese medicinal materials is not good enough due to low levels.
For this reason, the “incorporating the provision and use of proprietary Chinese medicines into monitoring and evaluation” mentioned in the “Opinions” is crucial.
Liang Jialin said that at present, the field of Chinese patent medicines has not particularly promoted the consistency evaluation of quality and efficacy, but some large Chinese patent medicine companies have built their own Chinese herbal medicine planting bases and have GAP (Good Agricultural Practice) certification.
“The country previously proposed to evaluate the evidence-based medicine after the market of Chinese patent medicines, that is, to evaluate their clinical efficacy. This evaluation is similar to the concept of drug consistency evaluation, which is to continuously track the quality of the Chinese patent medicine products that have won the bid. , Monitoring. The clinical efficacy of proprietary Chinese medicines will also be linked to their subsequent online qualifications and pricing rules for recruitment and procurement.” Liang Jialin said.
In fact, the subdivision of “Chinese medicine formula granules” has taken the lead in launching evaluations. On November 1, the first batch of national standards (160) of traditional Chinese medicine formula granules was officially implemented, which provides guarantee for the standardized process production, quality and safety of traditional Chinese medicine formula granules.
“This shows that the product quality of Chinese medicine formula granules has a unified standard and threshold.” Liang Jialin said that in the next stage, it is expected that Chinese medicine formula granules will first enter the national level of centralized procurement of Chinese patent medicines, followed by slightly less standardized Chinese patent medicines, and finally It’s Chinese herbal medicine pieces. “
The capital market reacted strongly
Xinhua News Agency announced on the 31st that “7 provinces including Shanghai, Zhejiang, Jiangxi, Shandong, Hunan, Guangdong, and Sichuan were the first batch to be approved to build national comprehensive reform demonstration zones for traditional Chinese medicine.”
Affected by a series of Chinese medicine policies, as of the close of the market on the 31st, the average increase of the Chinese medicine industry sector was 5.36%; and the Chinese medicine concept (BK0615) has increased by more than 22.4% since September.
Among them, Zuoli Pharmaceutical (300181.SZ) ranked first with an increase of nearly 20%. The company is mainly engaged in the development of downstream Chinese medicine products of Wulingshen; other proprietary Chinese medicine companies with an increase of more than 10%, including Hongri Pharmaceutical (300026.SZ) , Zeda Yisheng (688555.SH), Kaikai Industry (600272.SH), Jinghua Pharmaceutical (002349.SZ), etc.
According to an analysis by Guojin Securities, the “Opinions” include some Chinese herbal medicines, proprietary Chinese medicines, and traditional Chinese medicine preparations in medical institutions into the medical insurance catalog. At the same time, the pricing mechanism is clarified, and the medical insurance fixed-point scope of Chinese medical drugs is further delineated. This “is expected to increase the amount of Chinese medicine in the hospital.” The “Opinions” will include Chinese herbal medicines that comply with the “Prescription Management Measures” and the “Management Standards of Chinese Herbal Medicines in Hospitals” but exceed the usual dosage prescribed by the “Pharmacopoeia of the People’s Republic of China”. Pharmaceutical dosage”.
IFC Securities also stated that the “Opinions” demonstrate the government’s emphasis on the Chinese medicine industry and its confidence in the future development of the industry. In the future, well-established brand names and strong companies in technological innovation and enhancement are expected to stand out.
The reporter also noticed that the “Opinions” will advance the reform of the payment method of traditional Chinese medicine, “explore the implementation of TCM disease types according to the value of the disease, select the types of medical diseases, reasonably determine the scores, and implement dynamic adjustments. Priority will be given to the advantages of traditional Chinese medicine issued by the state. The types of diseases are included in the scope of payment by type”.
Some medical insurance experts believe that considering the imminent reform of medical insurance payment payment, under the emergency plan, the special items of traditional Chinese medicine can continue to be paid in DRG groups, and those that are not read will be paid separately; in the short term, the term in the clinical diagnosis and treatment of traditional Chinese medicine can be Part 3 “Therapeutics” is included in the DRG group; in the long run, the first part of “disease” and the second part of “symptoms” in the clinical diagnosis and treatment terminology of TCM can be included in the DRG group, and the groups are grouped by the system of Chinese medicine.
.